NCT00611078

Brief Summary

The purpose of this study is to assess the feasibility of conducting a large hospital based case control study of the role of dioxins and dioxinlike polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2004

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2004

Completed
3.4 years until next milestone

First Submitted

Initial submission to the registry

January 25, 2008

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 8, 2008

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2011

Completed
Last Updated

January 20, 2011

Status Verified

January 1, 2011

Enrollment Period

6.3 years

First QC Date

January 25, 2008

Last Update Submit

January 19, 2011

Conditions

Soft Tissue Sarcoma

Keywords

Soft Tissue Sarcomaenvironmentpollutants04-088

Outcome Measures

Primary Outcomes (1)

  • enrollment of 60 participants

    Conclusion of the study

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with Soft Tissue Sarcoma at Memorial Sloan Kettering Cancer Center.

You may qualify if:

  • Patients with Soft tissue sarcoma at MSKCC are eligible for this study if they meet the following criteria:
  • Between 18 and 79 years of age
  • were diagnosed within the previous 6 months with primary soft tissue sarcoma of one of the following histologic subtypes: liposarcoma, leiomyoscaroma, MFH, or synovial sarcoma
  • are enrolled in protocol 02-060 ("Novel Biochemical and Molecularr Determinants for Soft Tissue Sarcoma"; PI, Dr. Samuel Singer)
  • controls will be eligibile for this study if they meet the following criteria
  • are b/w 18-79 years of age
  • have no prior history of cancer (other than non melanoma skin cancer)

You may not qualify if:

  • Individuals will be excluded if they
  • are unable to sign informed consent for medical or other reasons
  • do not speak english

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood, adipose tissue

MeSH Terms

Conditions

Sarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms

Study Officials

  • Lawrence Engel, Ph.D.

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 25, 2008

First Posted

February 8, 2008

Study Start

September 1, 2004

Primary Completion

January 1, 2011

Study Completion

January 1, 2011

Last Updated

January 20, 2011

Record last verified: 2011-01

Locations

US(1)